Justify dose of Bilastine: CDSCO Panel tells Glenmark on FDC of Bilastine, Dextromethorphan ,Phenylephrine Syrup

Published On 2022-05-17 13:40 GMT | Update On 2023-10-12 12:02 GMT

New Delhi: Rejecting the pharmaceuticals major Glenmark proposal for bioequivalence (BE) study waiver of fixed dose combination drug Bilastine 3.3mg plus Dextromethorphan Hydrobromide 10mg plus Phenylephrine Hydrochloride 5mg Syrup, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has opined the firm to justify the dose of Bilastine in...

This came after the firm presented the Phase III clinical trial protocol and requested for BE study waiver before the committee.

Bilastine is an anti-histamine which is used to treat allergies. It works by blocking the effects of a chemical messenger known as 'histamine', which is naturally involved in allergic reactions. In short, it helps to relieve the discomfort and unpleasant symptoms that occurred due to allergic conditions, like blocked/runny/itchy nose, red/watery eyes, and skin rashes.

Dextromethorphan Hydrobromide an anti-tussive (relieve cough) medication primarily used to treat dry cough. It works by blocking the cough receptor present in the brain, which is known to cause cough.

Phenylephrine is an alpha-1 adrenergic agonist that mediates vasoconstriction1 and mydriasis depending on the route and location of administration. Systemic exposure to phenylephrine also leads to agonism of alpha-1 adrenergic receptors, raising systolic and diastolic pressure as well as peripheral vascular resistance. Increased blood pressure stimulates the vagus nerve, causing reflex bradycardia.

At the recent SEC for Pulmonary held on 28.04.2022, the expert panel reviewed the Phase III clinical trial protocol and request for the BE study waiver in detail.

During the presentation, the committee noted that Bilastine 6.6 mg t.i.d is not approved internationally.

In addition the expert panel suggested that clinical trial protocol for appropriate phase of the study should be revised accordingly and sedation should also be included in the clinical trial protocol as one of the endpoint.

After detailed deliberation, the committee recommended that the firm should initially justify the dose of Bilastine in the proposed FDC for further review by the committee.

Also Read:CoSara Diagnostics gets CDSCO clearance for Hepatitis C Viral Load Test

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Justify dose of Bilastine: CDSCO Panel tells Glenmark on FDC of Bilastine, Dextromethorphan ,Phenylephrine Syrup

Similar News